13F Holdings
中文EN

PRLD Prelude Therapeutics Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1678660 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY105.4%
TTM net income YoY52.3%
TTM EPS YoY59.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-283.9%
Net margin-247.1%
FCF margin-129.6%
EBITDA margin-277.0%

Returns

ROE-58.4%
ROA-39.5%
ROIC (approx.)-86.6%
Asset turnover0.16x

Leverage & solvency

Liabilities / assets29.3%
Debt / equity0.00x
Current ratio4.20x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.52x
Accruals ratio-18.8%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$12.14M$7.00M———
R&D expense$94.30M$118.00M$103.39M$92.89M$86.78M
SG&A expense$22.41M$28.72M$28.88M$30.65M$26.96M
Operating income-$104.57M-$139.71M-$132.28M-$123.54M-$113.73M
Pretax income-$99.50M-$127.20M———
Income tax$0$0———
Net income-$99.50M-$127.17M-$121.83M-$115.44M-$111.69M
EBITDA-$102.86M-$137.94M-$131.11M-$122.22M-$112.82M
EPS (basic)-1.29-1.68-2.02-2.44-2.43
EPS (diluted)-1.29-1.68-2.02-2.44-2.43
Weighted avg. shares (diluted)76.96M75.81M60.36M47.37M46.05M
Balance sheet
Cash & equivalents$35.26M$12.47M$25.29M$30.61M$31.83M
Short-term investments$67.96M$121.14M$207.64M$171.12M$259.40M
Current assets$105.69M$135.90M$235.59M$204.38M$295.12M
PP&E, net$5.11M$6.77M$7.33M$4.91M$3.93M
Total assets$141.31M$175.51M$277.67M$220.50M$305.10M
Current liabilities$52.99M$25.64M$21.83M$21.70M$19.20M
Total liabilities$72.68M$44.06M$40.58M$25.06M$19.20M
Shareholders' equity$68.64M$131.46M$237.09M$195.44M$285.90M
Cash flow statement
Operating cash flow-$56.30M-$102.89M-$107.06M-$83.73M-$83.53M
Capital expenditure$67,000$764,000$3.51M$3.02M$2.32M
Free cash flow-$56.37M-$103.65M-$110.58M-$86.75M-$85.85M
Investing cash flow$53.46M$90.19M-$34.65M$81.69M-$263.80M
Financing cash flow$24.82M-$120,000$136.40M$815,000$164.90M
Depreciation & amortization$1.71M$1.77M$1.17M$1.32M$915,000
Stock-based compensation$11.91M$21.34M$25.62M$25.14M$20.93M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.